Uromigos on ASCO 2023: Kidney Cancer | GU Oncology Now

Uromigos-ASCO 2023-Kidney Cancer

Episode 251: Final Part of VEGF/TKI vs IPI/NIVO Discussion

The UromigosThe Uromigos | July 25, 2023

Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.

Episode 249: ASCO 2023 - IPI/NIVO vs VEGF/PD1 in Kidney Cancer With Mike Atkins

The UromigosThe Uromigos | June 21, 2023

The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.

Episode 245: ASCO 2023 - CONTACT-03 and Cabozantinib +/- Atezolizumab in RCC

The UromigosThe Uromigos | August 1, 2023

Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.

Episode 241: Statistics for Clinical Trials and RCC at ASCO 2023

The UromigosThe Uromigos | August 1, 2023

Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.

Advertisement

Advertisement